BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard Sells 10,000 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $20.18, for a total value of $201,800.00. Following the sale, the chief marketing officer now owns 108,894 shares of the company’s stock, valued at approximately $2,197,480.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Todd Berard also recently made the following trade(s):

• On Wednesday, May 29th, Todd Berard sold 345 shares of BioLife Solutions stock. The stock was sold at an average price of $21.78, for a total value of $7,514.10.
• On Friday, May 17th, Todd Berard sold 73 shares of BioLife Solutions stock. The stock was sold at an average price of $22.18, for a total value of $1,619.14.
• On Thursday, April 18th, Todd Berard sold 332 shares of BioLife Solutions stock. The stock was sold at an average price of $15.31, for a total value of $5,082.92.
• On Monday, April 15th, Todd Berard sold 10,000 shares of BioLife Solutions stock. The stock was sold at an average price of $15.67, for a total value of $156,700.00.
• On Wednesday, March 27th, Todd Berard sold 515 shares of BioLife Solutions stock. The stock was sold at an average price of $17.99, for a total value of $9,264.85.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $19.96 on Wednesday. The firm has a market capitalization of $919.56 million, a P/E ratio of -14.06 and a beta of 1.80. BioLife Solutions, Inc. has a 1-year low of $8.92 and a 1-year high of $24.35. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 1.77. The business’s 50-day simple moving average is $19.47 and its 200-day simple moving average is $17.80.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.06. The business had revenue of $31.73 million for the quarter, compared to analyst estimates of $29.30 million. BioLife Solutions had a negative return on equity of 12.89% and a negative net margin of 45.84%. During the same period in the previous year, the company posted ($0.27) EPS. Equities analysts predict that BioLife Solutions, Inc. will post -0.44 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on BLFS. StockNews.com upgraded BioLife Solutions to a “sell” rating in a research report on Friday, May 10th. Jefferies Financial Group began coverage on BioLife Solutions in a research note on Thursday, April 4th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, Benchmark raised BioLife Solutions from a “neutral” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Monday, May 13th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.67.

Institutional Investors Weigh In On BioLife Solutions

Several hedge funds have recently modified their holdings of BLFS. Nisa Investment Advisors LLC raised its holdings in shares of BioLife Solutions by 167.2% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 1,020 shares during the period. GAMMA Investing LLC purchased a new stake in shares of BioLife Solutions during the 4th quarter valued at about $41,000. Register Financial Advisors LLC purchased a new stake in shares of BioLife Solutions during the 1st quarter valued at about $96,000. Dark Forest Capital Management LP purchased a new stake in shares of BioLife Solutions during the 3rd quarter valued at about $223,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in shares of BioLife Solutions during the 1st quarter valued at about $229,000. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.